Table 1

Inclusion and exclutsion criteria

Inclusion criteria	Exclusion criteria
▸ Histological proven soft tissue sarcoma except the following entities: angiosarcoma, gastrointestinal stromal tumor (GIST), Ewing-sarcoma, dermatofibrosarcoma protuberans, embryonal rhabdomyosarcoma ▸ The tumour appears to be resectable or resectability is expected after prior treatment ▸ Age of 18 years or older ▸ Eastern cooperative oncology group (ECOG) performance status 0 or 1 ▸ Normal organ function (kidney, liver, bone marrow) ▸ Written informed consent ▸ Sufficient contraception (Pearl-Index <1)	▸ Intake of inductors or inhibitors of CYP3A4 ▸ Prior therapy with receptor tyrosine kinase inhibitors or conventional chemotherapy until 4 weeks before study inclusion ▸ History of myocardial infarction, cardiac insuffiency (NYHA grade III or IV), apoplex, thrombosis or embolism ▸ Major surgery 4 weeks before study inclusion ▸ Uncontrolled medical disease such as art. hypertension or diabetes mellitus ▸ Antihypertensive medication with more than 2 drugs ▸ Therapeutical anticoagulation with coumadin or similar medication (this does not include ASS and low-dose heparins medication) ▸ Known allergy or intolerance of study medication ▸ Known hereditary coagulopathy ▸ History or other malignancies during the last year before study inclusion ▸ Metastatic disease with the exception of a singular metachronous metastatic lesion ▸ Pregnancy ▸ Known allergy to sunitinib

Inclusion criteria

Exclusion criteria

▸ Histological proven soft tissue sarcoma except the following entities: angiosarcoma, gastrointestinal stromal tumor (GIST), Ewing-sarcoma, dermatofibrosarcoma protuberans, embryonal rhabdomyosarcoma
▸ The tumour appears to be resectable or resectability is expected after prior treatment
▸ Age of 18 years or older
▸ Eastern cooperative oncology group (ECOG) performance status 0 or 1
▸ Normal organ function (kidney, liver, bone marrow)
▸ Written informed consent
▸ Sufficient contraception (Pearl-Index <1)

▸ Intake of inductors or inhibitors of CYP3A4
▸ Prior therapy with receptor tyrosine kinase inhibitors or conventional chemotherapy until 4 weeks before study inclusion
▸ History of myocardial infarction, cardiac insuffiency (NYHA grade III or IV), apoplex, thrombosis or embolism
▸ Major surgery 4 weeks before study inclusion
▸ Uncontrolled medical disease such as art. hypertension or diabetes mellitus
▸ Antihypertensive medication with more than 2 drugs
▸ Therapeutical anticoagulation with coumadin or similar medication (this does not include ASS and low-dose heparins medication)
▸ Known allergy or intolerance of study medication
▸ Known hereditary coagulopathy
▸ History or other malignancies during the last year before study inclusion
▸ Metastatic disease with the exception of a singular metachronous metastatic lesion
▸ Pregnancy
▸ Known allergy to sunitinib